Remove Medicare Remove Outcomes Remove Peripheral Arterial Disease
article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

article thumbnail

SCAI Scientific Sessions 2025 to Feature Presentations on TAVR, PAD and PE 

DAIC

tim.hodson Fri, 03/14/2025 - 16:12 SCAI Scientific Sessions 2025 will take place May 1 to 3, attheWalter E. Washington Convention Center in Washington, DC.

TAVR 52
article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. Updated estimates for the burden of chronic limb-threatening ischemia in the Medicare population, Journal of Vascular Surgery, Volume 77, Issue 6, 2023, 1760-1775 2 Seguchi M.,

article thumbnail

Outpatient vascular care : Good, bad or ugly?

Dr. Anish Koka

Most have gotten used to egregiously bad coverage of current events that fills the pages of today’s New York Times, but even by their now very low standards a recent telling of a story about peripheral artery disease was very bad. The Times also briefly touches on some other patients of Mustapha who had bad outcomes.

article thumbnail

R3 Vascular Receives WGC IRB Approval for its ELITE-BTK Pivotal Trial of its Next Generation Bioresorbable Scaffold

DAIC

a medical device company dedicated totreating peripheral arterial disease (PAD), recently announceit received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDEDrug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD).